Chemotherapy targeted to cancers through tumoral hormone receptors.
about
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesMedical treatment for gastro-entero-pancreatic neuroendocrine tumoursLapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumorsThe novel fusion proteins, GnRH-p53 and GnRHIII-p53, expression and their anti-tumor effectThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsSomatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231Bombesin receptor-mediated imaging and cytotoxicity: review and current statusTherapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumorsTargeted drug delivery in cancer therapy.Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]Cancer treatment using peptides: current therapies and future prospectsIssues related to targeted delivery of proteins and peptides.New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK.Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cellsExpression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonistsSomatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Receptor-mediated tumor targeting based on peptide hormones.Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).Gonadotropin-releasing hormone targeting for gonadotroph ablation: an approach to non-surgical sterilization.Agonists of luteinizing hormone-releasing hormone in prostate cancer.Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectivesThe use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers.Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.Oligonucleotide-based theranostic nanoparticles in cancer therapy.Gonadotropin‑releasing hormone inhibits the proliferation and motility of nasopharyngeal carcinoma cells.Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety.
P2860
Q24643524-D4FE95CA-267A-435F-820A-DAF0CA165E9DQ26751659-0C8B07B3-8D03-487B-99E0-4B2866208AF9Q28292264-B66E2B90-3A85-498B-9EBA-D0965F46A1C6Q28534798-F5DF6342-65E5-4152-B952-A885E964BBE0Q30486707-8EF507E4-4303-43E8-A7D4-96E3251B6C90Q33753449-58CCF994-FA10-445A-B4B0-E993C9950571Q34101055-A46FEFED-0E4E-4ADD-ABB8-234133E4EA62Q34274245-ED092E29-7326-4E96-A23C-B7FFF6633AFEQ34486740-80189917-6D76-444F-AFA7-7A686D4A7225Q34684387-7BA06EDB-84CF-49A1-9BA0-B2385421FFEEQ34772221-79ACDE7A-E317-46C4-8E31-EF9D3625C706Q34894406-0001AEF4-7058-4C68-A4BF-811E7A029E9FQ35162175-93C1F012-BF8A-49F4-9198-118F01621232Q35340967-A78A92A2-0044-4D89-8B08-61148195773CQ36200150-94E2E950-23E0-4862-B4FD-3AC1563C9ED2Q36202016-E901049A-664E-445D-B9B3-6383B6EEA119Q36236479-E3C154E3-2E10-4BCB-B5E6-680B1ECD6362Q36515785-2D2AEA5C-58DF-4E88-997A-1A3C90A6C561Q36616311-5D5A2B96-022C-47CF-872C-70417EEAC10AQ36748502-3AFFECDD-D022-4697-9F43-091E2810AA82Q37012088-9E0F0358-3995-4AAE-B653-031667B04223Q37034254-A6E3DC11-12A6-4E06-BC63-3DA79E2BCF88Q37093547-8A03C790-F192-480D-890F-5B6A033EFE41Q37178660-6710CB5D-6BEC-4968-A5DE-E38CDE589C92Q37323454-9A00B832-196D-4A44-84C5-8EE0EC6FFC82Q37381602-E19B306A-36F3-41FB-80E6-8DAAE109B78DQ37495105-47112C16-9E7C-4682-9F75-7E6BC143B235Q37564373-4C834564-A13D-4414-8CFA-0A976AB056F4Q37641368-BFC959DE-5B21-4F05-928C-4C439682571FQ37724516-AD509438-52F5-4BDC-A95E-F7AB913A64D1Q37859389-2C8AB7BD-40B2-4DD6-A2BF-119B391E211EQ38007373-B2B0C677-8D53-4C87-9AEA-DE33AD5CABC5Q38029046-9F5617A3-B5CA-40CC-A6C6-4A1619D45BBCQ38132229-C2DE6502-FF0F-4CE5-8172-D9FE9253A189Q38216009-E8458F38-8B55-411E-A621-08B0A101F8F9Q38472348-54245DC6-E947-497F-B721-4B7FA68CBAF2Q38756598-8DE8F26F-6BA9-49C6-BF12-AD75A0C5C38FQ38814327-A705DE2B-C4D5-4935-BDF1-47EA67850410Q38855783-CCEF9356-DEB8-4B41-8565-C0A8FB02EFCDQ38865705-D0039F3C-C338-4A01-92EA-7FADB0335E60
P2860
Chemotherapy targeted to cancers through tumoral hormone receptors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Chemotherapy targeted to cancers through tumoral hormone receptors.
@ast
Chemotherapy targeted to cancers through tumoral hormone receptors.
@en
type
label
Chemotherapy targeted to cancers through tumoral hormone receptors.
@ast
Chemotherapy targeted to cancers through tumoral hormone receptors.
@en
prefLabel
Chemotherapy targeted to cancers through tumoral hormone receptors.
@ast
Chemotherapy targeted to cancers through tumoral hormone receptors.
@en
P1476
Chemotherapy targeted to cancers through tumoral hormone receptors.
@en
P2093
Attila Nagy
P304
P356
10.1016/J.TEM.2004.07.002
P577
2004-09-01T00:00:00Z